M&A Regulatory & Antitrust Management

Problem class

M&A transactions increasingly face multi-jurisdiction regulatory review — merger control, foreign investment screening (CFIUS, EU FDI), sector-specific approvals. Without structured regulatory management, deals face delays, conditions, or prohibition.

Mechanism

Pre-signing regulatory assessment evaluates filing requirements across relevant jurisdictions and identifies potential antitrust concerns (market concentration, competitive overlap). Filing preparation produces notifications with market definitions, competitive analysis, and remedy proposals. Regulatory engagement manages examiner interactions, information requests, and hearing preparation. Condition compliance tracks behavioral and structural remedies imposed as conditions of approval.

Required inputs

• Transaction details for filing threshold analysis per jurisdiction
• Market definition and competitive overlap analysis
• Regulatory filing templates per jurisdiction (HSR, EU Form CO, etc.)
• Foreign investment screening analysis (CFIUS, EU FDI regulation)

Produced outputs

• Multi-jurisdiction filing timeline and strategy
• Regulatory submissions with market analysis and remedy proposals
• Clearance tracking across all required jurisdictions
• Condition compliance programs for imposed remedies

Industries where this is standard

• All transactions above merger-control filing thresholds globally
• Technology with intense antitrust scrutiny from US DOJ, EU, and UK CMA
• Healthcare and pharmaceutical with FTC and EU DG COMP review
• Defense and critical infrastructure under foreign investment screening
• Financial services with banking and insurance regulatory approvals

Counterexamples

• Announcing deals without pre-signing regulatory risk assessment creates public commitments that are difficult to unwind if regulators impose prohibitive conditions.
• Treating regulatory approval as a legal department exercise without business-team involvement produces market-definition arguments disconnected from commercial reality.

Representative implementations

• EU DG Competition blocked the Illumina/GRAIL deal in 2022 and required unwinding — demonstrating that even completed acquisitions face regulatory reversal.
• FTC scrutiny of Microsoft/Activision ($69B, completed 2023) set new precedents for tech-sector merger review, taking 21 months from announcement to close.
• CFIUS foreign investment reviews increased 25% in 2024, with expanded scope covering technology, data, and critical infrastructure transactions.

Common tooling categories

Regulatory filing management platforms, merger-control analysis tools, CFIUS screening assessments, and condition-compliance tracking systems.